(Q40239582)

English

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

scientific article published on 6 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (English)

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

15

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

John D Hainsworth

10

object named as

John D Hainsworth

1 reference

Europe PubMed Central

18 September 2017

PMC publication ID

7

object named as

Karim Fizazi

1 reference

Europe PubMed Central

18 September 2017

PMC publication ID

Mary-Ellen Taplin

20

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

30

object named as

Fred Saad

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

27

object named as

Howard I Scher

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

11

object named as

Tomasz M Beer

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Celestia Higano

19

object named as

Celestia S Higano

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

26

object named as

Eric J Small

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

author name string

Dana E Rathkopf

1

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Matthew R Smith

2

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Johann S de Bono

3

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Christopher J Logothetis

4

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Neal D Shore

5

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Paul de Souza

6

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Peter F A Mulders

8

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Paul Mainwaring

9

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Scott North

12

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Yves Fradet

13

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Hendrik Van Poppel

14

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Thomas W Flaig

16

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Eleni Efstathiou

17

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Evan Y Yu

18

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Thomas W Griffin

21

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Mary B Todd

22

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Margaret K Yu

23

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Youn C Park

24

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Thian Kheoh

25

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Arturo Molina

28

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

Charles J Ryan

29

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

language of work or name

0 references

publication date

6 March 2014

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

European Urology

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

66

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

5

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

815-825

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Androgen receptor antagonists in castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Abiraterone acetate for the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Novel molecular targets for the therapy of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Castration-resistant prostate cancer: many treatments, many options, many challenges ahead

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

22 September 2017

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

25 September 2017

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

20 August 2018

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

20 August 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

20 August 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418928

20 August 2018

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24647231

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.EURURO.2014.02.056

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40239582&oldid=2186406162"